RTS Life Science Acquired by Entologi

One of the UK’S fastest growing engineering groups, Entologi, is to buy RTS Life Science incorporating RTS’s specialist robotics and industrial technology group.
Gary Walsh, RTS Managing Director, commented: “This acquisition represents a platform for expansion for us, whilst at the same time adding significantly to the
Entologi Group.”

With a blue chip client list encompassing all ten of the top ten global pharmaceutical companies, RTS is a market leader in compound management and pharmaceutical testing solutions and becoming a leading supplier in the rapidly expanding biobanking arena. RTS already uses technology and products from two
other companies within the Entologi Group, HMK and Specific Environments.

“The acquisition of a company whose ethos is already aligned with ours is ideal. Being part of a bigger Group should allow the RTS team the freedom to concentrate on exploiting our combined technology to bring new products to market while continuing to develop its long term customer relationships,” said Entologi Chairman, Neville Buckley.

RTS’s management team insists that it is very much “business as usual” for them. “I believe firmly that the company will benefit greatly from the backing of a Group growing both organically and by acquisition”, comments Walsh. “We will also be allowed the luxury of total focus on our core strengths without the distractions that inevitably accompany the management of a stand-alone Public Limited Company.”